Objective: Concern over perioperative and long-term durability of lower extremity revascularizations among active smokers is a frequent deterrent for vascular surgeons to perform elective lower extremity revascularization. In this study, we examined perioperative outcomes of lower extremity endovascular (LEE) revascularization and open lower extremity bypass (LEB) in active smokers with intermittent claudication (IC) and critical limb ischemia (CLI).
Peripheral arterial disease (PAD) is an affliction affecting nearly 200 million individuals worldwide, ranging from asymptomatic disease to severe limb-threatening ischemia. 1 Smoking has been clearly implicated as one of the most significant modifiable risk factors contributing to both the development of PAD and progression of disease once diagnosed. [2] [3] [4] [5] [6] Historical observational data have shown that continued smoking is associated with higher rates of amputation, death, and myocardial infarction (MI) in patients with PAD compared with those who quit. 7 The
Society for Vascular Surgery practice guidelines for atherosclerotic occlusive disease of the lower extremities include smoking cessation as a Grade IA recommendation in the management of asymptomatic disease and intermittent claudication (IC).
bypass surgery. [10] [11] [12] [13] In addition, smoking cessation is associated with decreased mortality and improved amputation-free survival among patients with symptomatic PAD. 14 Because traditional open surgery and more complex endovascular options are available for treating symptomatic PAD, great variation exists in practice patterns among vascular specialists who perform these treatments for patients with IC and critical limb ischemia (CLI). 15 Specifically in smokers, practitioners must weigh the effect of continued smoking on outcomes after peripheral arterial interventions and decide when to offer open or endovascular revascularization to patients with nonlimb-threatening ischemia. In this regard, there are limited contemporary data regarding the comparative outcomes among current smokers undergoing open lower extremity bypass (LEB) and lower extremity endovascular (LEE) revascularization for advanced peripheral arterial disease. In this study, we sought to evaluate the perioperative outcomes of LEE revascularization and LEB in a nationwide contemporary cohort of current smokers with IC and CLI.
METHODS
Data source. We retrospectively analyzed the American College of Surgeons (ACS) National Surgical Quality Improvement Program (NSQIP) Targeted Open Lower Extremity Revascularization and Lower Extremity Endovascular Revascularization Participant Use Data Files (PUFs) consisting of all qualifying procedures performed from January 1, 2011, to December 31, 2014, inclusively. The ACS NSQIP is a nationally validated, risk-adjusted, outcomes-based program to measure and improve the quality of surgical care in the United States. The data in the general and procedurally targeted databases are collected and entered by surgical clinical reviewers who are certified by the ACS. Strict variable definitions are used when data are collected to ensure consistency across participating centers, and periodic auditing is used to ensure accuracy. 16 The procedurally targeted databases collect procedurespecific demographics, anatomic, and perioperative details, and 30-day postoperative outcomes data, which first became available in 2011. We then merged the targeted databases with the general PUF by the deidentified Case ID, allowing for both procedure-specific and general variables and outcomes collected in NSQIP to be analyzed for all cases. The NSQIP database is exempt from requiring informed consent from individual patients and does not require Institutional Review Board approval for analysis.
Cohort and variables. Patients who underwent LEB or LEE revascularization between 2011 and 2014 were identified from the NSQIP targeted database. The patients in this surgical group who were reported to have been smokers within the past year, a defined variable in the general NSQIP PUF, were selected for our study group.
Preoperative variables analyzed were age, gender, race, and comorbid conditions, including chronic obstructive pulmonary disease, congestive heart failure, hypertension requiring medication, diabetes mellitus, end-stage renal disease, chronic steroid use, obesity, dependent functional status, and high-risk physiology, defined as a recent adverse cardiac event within the past 6 months. Preoperative use of antiplatelet therapy, statins, and b-blockers was evaluated. Data regarding preoperative ankle-brachial indices were also identified, as were whether the procedure performed was deemed an emergency and whether the indication for the procedure was claudication, rest pain, or tissue loss. The latter two comprised the definition of the CLI cohort.
Perioperative variables analyzed were type of anesthesia used, below-knee vs above-knee target, bleeding requiring intraoperative or postoperative transfusion, and operative time. A below-knee target was defined as tibial angioplasty or stenting for the LEE group and bypass distal to the popliteal artery for the LEB group. Postoperative outcomes examined were 30-day mortality and postoperative occurrence of MI, stroke, and wound complications, major reintervention on the treated arterial segment, major amputation, venous thromboembolism, frequency of discharge to home vs another facility, and unplanned readmission. Hospital length of stay was also tabulated.
Statistical analysis. Univariate and multivariate analyses were performed comparing current smokers who underwent LEE with those who underwent LEB. Demographics, perioperative variables, and postoperative outcomes defined in the previous section were analyzed. congestive heart failure, diabetes mellitus, hypertension, preoperative end-stage renal disease, preoperative functional status, preoperative use of antiplatelet therapy, recent adverse cardiac events (#6 months), emergency procedures, indication for procedure, and whether the intervention was performed for an above-knee vs below-knee arterial target, were entered into a multivariable logistic regression model to estimate adjusted odds ratios (ORs) with 95% confidence intervals (CIs) for the following primary outcomes: 30-day mortality, major amputation, major reintervention, wound complication, MI or stroke, hospital readmission #30 days, and overall hospital length of stay. A subgroup analysis also compared LEE vs LEB in smokers whose procedure was performed exclusively for IC and those performed for CLI. Univariate and multivariate analyses were performed for these comparisons as well. Statistical significance was defined as P < .05, and the Holm method was used to adjust P values for multiple comparisons. The statistical analysis was performed with SPSS 23.0 software (IBM Corp, Armonk, NY).
RESULTS
Between January 1, 2011, and December 31, 2014, there were 12,655 cases of LEE revascularization and LEB identified in the ACS-NSQIP procedurally targeted databases. Of these patients, 4706 (37.2%) were current smokers, which comprised the study cohort. The cohort was a mean age of 62.6 years, with 65.8% male and 69.1% white. Of all procedures done in current smokers, 35.3% (n ¼ 1661) were performed for the indication of IC, and 27.9% (n ¼ 1313) were performed for below-knee target vessels. Overall 30-day mortality was 0.8%.
In this study cohort, 1497 procedures (31.8%) were LEE and 3209 (68.2%) were LEB. When LEE revascularization was compared with LEB, age, race, rates of chronic obstructive pulmonary disease, congestive heart failure, obesity, chronic steroid use, preoperative dependent functional status, and frequency of recent adverse cardiac events were similar between the two groups. Patients in the LEE group were less frequently male (62.1% vs 67.5%; P < .01), and had higher rates of hypertension requiring medication, diabetes mellitus, preoperative end-stage renal disease, and preoperative use of antiplatelet therapy (all P < .03). There was no difference in the incidence of the procedure being done emergently vs electively between the two groups (4.7% vs 5.9%; P ¼ .11). IC was the indication for 44.4% of the LEE procedures but for only 31.1% of the LEB procedures. The remaining 68.9% of LEB were performed for patients with CLI (Table I) .
The procedure was performed under general anesthesia for 30.3% of the LEE patients and for 95.7% of the LEB patients. Mean operative time was 111.9 minutes for the LEE revascularization and was 238.8 minutes for LEB procedures. LEE procedures required fewer intraoperative or postoperative transfusions compared with LEB (7.5% vs 21.0%; P < .01). In addition, LEE revascularization was much less frequently performed for below-knee targets than LEB (13.4% vs 34.7%; P < .01).
In the unadjusted outcomes analysis, 30-day mortality remained low in both the LEE and LEB groups (0.6% and 0.9%, respectively). However, the incidence of MI was higher in the LEB group (2.1% vs 0.9%; P ¼ .01). Wound complications were significantly lower in the LEE group (3.1% vs 13.2%; P < .01), but the progression to major amputation #30 days was higher in the LEE group (3.2% vs 2.1%; P < .01). The reintervention rate on the treated arterial segment was similar between the LEE and LEB groups (5.1% vs 5.2%; P ¼ .90). The venous thromboembolism rate was higher in the LEB group (0.9% vs 0.3%; P ¼ .02) as was rate of unplanned readmission (10.3% vs 5.7%; P < .01). Mean hospital length of stay was also longer in the LEB group (7.3 6 7.8 days vs 3.6 6 7.1 days; P < .01; Table II) .
Multivariate analyses, adjusted for age, sex, race, comorbid conditions, indication, and above-knee vs belowknee intervention, showed LEE revascularization had higher rates of reintervention on the treated arterial segment (OR, 1.52; 95% CI, 1.08-2.13; P ¼ .02) and lower wound complications (OR, 0.32; 95% CI, 0.23-0.45; P < .01), with a significantly shorter mean hospital length of stay (mean difference, 1.34 days; P < .01) compared with LEB. There was no statistically significant difference between LEE and LEB for mortality (OR, 0.44; P ¼ .13), major amputation (OR, 1.54; P ¼ .09), MI (OR, 0.649; P ¼ .21), or risk for unplanned readmission (OR, 0.795; P ¼ .12; Table III ).
IC subgroup. The 1661 patients undergoing LEE revascularization in the IC subgroup had higher rates of hypertension requiring medication, diabetes mellitus, and preoperative antiplatelet use, and were less frequently male (all P < .01). General anesthesia was used much more frequently in the LEB group (95.3% vs 23.6%; P < .01). While 85.9% of all LEB procedures were performed for above-knee arterial targets, LEE procedures were still more frequently done for above-knee targets (92.8% vs 81.2%; P < .01; Table IV) .
The LEE and LEB groups both had an extremely low 30-day mortality rate (0.2% and 0.7%, respectively), but MI occurred more frequently in the LEB group (1.0% vs 0.2%; P ¼ .04). Major reintervention on the treated arterial segment and major amputation were both similarly low among the LEE and LEB groups. However, wound complications were again higher in the LEB group than in the LEE revascularization group (9.6% vs 2.0%; P < .01; Table V) .
On multivariate analysis, major reintervention on the treated arterial segment remained higher in the LEE group (OR, 2.03; 95% CI, 1.01-4.09; P ¼ .04). But the LEE group had a lower risk of wound complications (OR, 0.23; 95% CI, 0.11-0.46; P < .01). In addition, multivariate analysis showed MI or stroke was significantly lower in the LEE revascularization group than in the LEB group (OR, 0.17; 95% CI, 0.03-0.83; P ¼ .03). There was no difference in risk of mortality, progression to early amputation, or hospital readmission #30 days (Table III) . CLI subgroup. In the subgroup of current smokers, 3045 patients underwent procedures for the indications of rest pain or tissue loss. The demographic makeup of patients undergoing the LEE revascularization and LEB was similar except for male gender (60.4% and 66.7%, respectively), diabetes mellitus (52.5% vs 40.5%; P < .01), and rate of preoperative end-stage renal disease (8.6% vs 5.1%; P < .01). The preoperative pharmacotherapy profiles were similar, as were the rates of preoperative dependent functional status. There was no difference in the emergent nature by which the procedures were performed. Below-knee targets were much more common in those undergoing LEB in this subgroup (41.9% vs 18.2%; P < .01). The use of general anesthesia remained higher in the LEB group compared with the LEE revascularization group (95.8% vs 35.5%; P < .01; Table VI) .
With regard to unadjusted outcomes, 30-day mortality, need for reintervention on the treated arterial segment, and rate of venous thromboembolism were similar between the two groups. The rate of MI or stroke, however, was higher in the LEB group (2.8% vs 1.4%; P ¼ .03), as was the rate of wound complications (14.8% vs 4.0%; P < .01). The need for unplanned readmissions was also higher in the LEB group (12.3% vs 7.2%; P < .01). Progression to major amputation #30 days was higher in the LEE treatment group (5.3% vs 2.8%; P < .01; Table VII) . On multivariate analysis, there was a trend toward increased major amputation in the LEE group, although this was not statistically significant (OR, 1.58; 95% CI, 0.93-2.69; P ¼ .09). The need for major reintervention on the treated arterial segment was similar between the LEE revascularization and LEB groups (OR, 1.38; 95% CI, 0.93-2.03; P ¼ .11). The incidence of MI or stroke (OR, 0.75; 95% CI, 0.37-1.52; P ¼ .42) between the two groups did not approach statistical significance. The LEE revascularization group again had lower risk of wound complications (OR, 0.36; 95% CI, 0.24-0.54; P < .01; Table III ). Risk for readmission was similar after adjustment (OR, 0.93; 95% CI, 0.59-1.16; P ¼ .28), and hospital length of stay remained shorter for the LEE revascularization group (mean difference, 1.17 days; P ¼ .02). 
DISCUSSION
Among active smokers undergoing LEE and LEB captured in the ACS NSQIP procedurally targeted databases, mortality within 30 days is low (0.8%). This did not differ between the two treatment groups, even when categorized by surgical indication. However, patients undergoing LEE were more frequently female and had higher rates of comorbidities, including hypertension, diabetes, end-stage renal disease on dialysis, and preoperative antiplatelet therapy. The LEB group appeared to have more advanced disease, as demonstrated by the higher rate of below-knee pathology and higher frequency of CLI. After adjustment, no differences were found in perioperative mortality, progression to amputation, MI or stroke, or need for readmission between the LEE and LEB populations. There was, however, higher need for reintervention on the treated arterial segment #30 days in the LEE group, whereas wound complications were higher in the LEB group.
That the larger incisions needed for open arterial dissection and vein harvesting resulted in statistically significantly higher rates of wound complications in LEB among active smokers is not surprising. Conversely, because endovascular procedures are commonly performed percutaneously, this likely results in decreased wound complications. The incidence of perioperative cardiovascular complications was similar between the LEE and LEB groups despite general anesthesia being more frequently used for the open procedures. This is consistent with a real-world study that examined smoking status and infrainguinal bypass outcomes and showed <2% risk of perioperative MI among active smokers. 12 When performing subgroup analysis of patients by indication, we again found that active smokers undergoing procedures for IC similarly had a higher need for reintervention #30 days in the LEE group, although progression to amputation, mortality, and risk for readmission were similar between the two groups. In the IC patients, however, risk for MI or stroke appeared significantly higher among those undergoing LEB compared with those undergoing LEE, a finding not seen in the analysis of the full cohort. This highlights the independent contribution of the endovascular approach to lower systemic cardiovascular complications among smokers with IC.
In patients with CLI, the primary outcomes of mortality, progression to amputation, need for reintervention, MI or stroke, and readmission were not statistically different between the two groups on adjusted analysis. Interestingly, there was a trend toward higher need for major amputation among smokers undergoing endovascular revascularization in this CLI subgroup. Conversely, there was a trend toward higher risk for major amputation in the LEB group for patients with IC. This may reflect that certain patients selected for endovascular revascularization with limb-threatening ischemia were at an inherently higher risk of requiring major amputation and were thought to be less ideal candidates for open bypass if there was any expectation of imminent failure. Overall rates of all major complications were higher in both LEE and LEB patients with CLI, likely due to the more acute and ill-nature of these patients. The constant finding among both IC and CLI subgroups and in the analysis of the entire cohort was that wound complications were higher and hospital lengths of stay were consistently longer among those undergoing bypass, although the difference in the hospital length of stay was 1.4 days, the clinical significance of which is debatable. Interestingly, despite the higher rate of wound complications, readmission and length of stay did not differ significantly after adjustment, although cost-analysis to determine any differences could not be performed. This likely reflects the stringent reporting of many minor wound complications that did not significantly alter the patient's postoperative hospital course. In addition, a surprisingly high 3.1% wound complication rate was noted for the LEE group, but may have represented the learning curve associated with percutaneous procedures which dated back to 2011, rather than infections, which are more likely to predominate the LEB wound complications. This study has several limitations, starting with its retrospective nature and possible selection bias, because these data are accrued from medical centers and practitioners who electively choose to report data into the NSQIP targeted database. Although this reflects realworld data from academic and community practitioners across the United States with a growing diversity of participation, may still be a source of bias. Because the ACS NSQIP database is inherently a procedural database, we were unable to assess smokers who were not offered revascularization. In our opinion, all modifiable risk factors, including efforts at smoking cessation, should be addressed before any intervention for nonlimbthreatening lower extremity ischemia is offered.
Although patients who underwent reinterventions #30 days were not considered as new patients in the database, we were also unable to specifically identify whether the same patient had multiple procedures within the data set. Another limitation is the lack of lesion-specific characteristics that were treated by LEB or LEE revascularization, such as lesion length, percentage of stenosis, and exact location. The extent of tissue loss or gangrene was similarly unavailable. We stratified by below-knee vs above-knee interventions, which was a variable reported in the database.
CONCLUSIONS
In active smokers undergoing lower extremity revascularization in the NSQIP targeted vascular database, perioperative mortality is low. LEE revascularization was more frequently performed in patients who were female, had more comorbidities, and for symptoms of IC. LEB was performed more frequently in patients with CLI and below-knee target vessels. Even when stratified by clinical risk factors and above-knee vs below-knee 
